Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31563741 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL27860489 | 0.74 | SLC6A2 (0.36) | SMN1; SMN2TSHRALDH1A1AOC3MAOA | |
| SCHEMBL4724209 | 0.74 | — | — | |
| SCHEMBL1851448 | 0.73 | DHFR (0.37) | SMN1; SMN2KMT2AHTTPIM1CSF1R | |
| SCHEMBL16921728 | 0.71 | HRH3 (0.41) | — | |
| SCHEMBL29661913 | 0.70 | CNR2 (0.40) | SMN1; SMN2TSHRKMT2AALDH1A1KDM4E | |
| SCHEMBL4747138 | 0.69 | CHRM2 (0.63) | SMN1; SMN2TSHRMAPTKMT2AALDH1A1 | |
| SCHEMBL16921940 | 0.69 | ESR1 (0.33) | — | |
| SCHEMBL16922002 | 0.69 | HRH3 (0.33) | — | |
| SCHEMBL3008603 | 0.69 | KDM4E (0.47) | SMN1; SMN2TSHRMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203841-A1 | TEMPLATE DIRECTED SPLIT AND MIX SYNTHESIS OF SMALL MOLECULE LIBRARIES | RASMUSSEN PETER BIRK (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20140235509-A1 | TEMPLATE DIRECTED SPLIT AND MIX SYNTHESIS OF SMALL MOLECULE LIBRARIES | RASMUSSEN PETER BIRK (DK) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | SMN1; SMN2 2868/4885TSHR 4585/4885MAPT 2893/4885 |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | SMN1; SMN2 2868/4885TSHR 4585/4885MAPT 2893/4885 |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | CBS, CTH, MTR | SMN1; SMN2 418/4885TSHR 4817/4885MAPT 1719/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | SMN1; SMN2 1639/4885TSHR 4556/4885MAPT 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.